Last Day
Biotechnology
Latest Valuation
- Trailing PE:
- Forward PE:
- Price Sales TTM:
- Price Book MRQ:
- Enterprise Value:
- Enterprise Value Revenue:
- Enterprise Value Ebitda:
- Beta:
Key Highlights
- Shares Outstanding:
- Market Capitalization:
- Market Capitalization Mln:
- EBITDA:
- PE Ratio:
- PEG Ratio:
- Wall Street Target Price:
- Book Value:
- Dividend Share:
- Dividend Yield:
- Earnings Share:
- EPS Estimate Current Year:
- EPS Estimate Next Year:
- EPS Estimate Next Quarter:
- EPS Estimate Current Quarter:
- Most Recent Quarter:
- Profit Margin:
- Operating Margin TTM:
- Return On Assets TTM:
- Return On Equity TTM:
- Revenue TTM:
- Revenue Per Share TTM:
- Quarterly Revenue Growth YOY:
- Gross Profit TTM:
- Diluted Eps TTM:
- Quarterly Earnings Growth YOY:
Basic Information
- Type:
- Name:
- Exchange:
- Currency Code:
- Currency Name:
- Currency Symbol:
- Country Name:
- Fiscal Year End:
- IPO Date:
- International Domestic:
- Sector:
- Industry:
- Address:
- Country:
- Listings:
- Web URL:
- Full Time Employees:
- Updated At:
- Gic Sector:
- Gic Group:
- Gic Industry:
- Gic SubIndustry:
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. Address: 61 North Beacon Street, Boston, MA, United States, 02134